Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsMüller, Thomas R
Chaudhry, M Zeeshan
Busch, Dirk H
MetadataShow full item record
AbstractAdoptive transfer of T cells expressing a transgenic T cell receptor (TCR) has the potential to revolutionize immunotherapy of infectious diseases and cancer. However, the generation of defined TCR-transgenic T cell medicinal products with predictable in vivo function still poses a major challenge and limits broader and more successful application of this "living drug." Here, by studying 51 different TCRs, we show that conventional genetic engineering by viral transduction leads to variable TCR expression and functionality as a result of variable transgene copy numbers and untargeted transgene integration. In contrast, CRISPR/Cas9-mediated TCR replacement enables defined, targeted TCR transgene insertion into the TCR gene locus. Thereby, T cell products display more homogeneous TCR expression similar to physiological T cells. Importantly, increased T cell product homogeneity after targeted TCR gene editing correlates with predictable in vivo T cell responses, which represents a crucial aspect for clinical application in adoptive T cell immunotherapy.
CitationCell Rep Med. 2021 Aug 17;2(8):100374. doi: 10.1016/j.xcrm.2021.100374.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
JournalCell reports. Medicine
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
- Authors: Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR, Falkenburg JHF, Heemskerk MHM
- Issue date: 2020 Jan 8
- Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function.
- Authors: Schober K, Müller TR, Gökmen F, Grassmann S, Effenberger M, Poltorak M, Stemberger C, Schumann K, Roth TL, Marson A, Busch DH
- Issue date: 2019 Dec
- Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection.
- Authors: Albers JJ, Ammon T, Gosmann D, Audehm S, Thoene S, Winter C, Secci R, Wolf A, Stelzl A, Steiger K, Ruland J, Bassermann F, Kupatt C, Anton M, Krackhardt AM
- Issue date: 2019 Apr
- Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.
- Authors: Schober K, Müller TR, Busch DH
- Issue date: 2020 Jun 1
- CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
- Authors: Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK
- Issue date: 2018 Jan 18